WO2013108272A3 - Blood stage malaria vaccine - Google Patents

Blood stage malaria vaccine Download PDF

Info

Publication number
WO2013108272A3
WO2013108272A3 PCT/IN2013/000041 IN2013000041W WO2013108272A3 WO 2013108272 A3 WO2013108272 A3 WO 2013108272A3 IN 2013000041 W IN2013000041 W IN 2013000041W WO 2013108272 A3 WO2013108272 A3 WO 2013108272A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
merozite
erythrocyte
vaccine
blood stage
Prior art date
Application number
PCT/IN2013/000041
Other languages
French (fr)
Other versions
WO2013108272A2 (en
Inventor
Deepak GAUR
Virander Singh CHAUHAN
Chetan Chitnis
Original Assignee
International Centre For Genetic Engineering And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Centre For Genetic Engineering And Biotechnology filed Critical International Centre For Genetic Engineering And Biotechnology
Publication of WO2013108272A2 publication Critical patent/WO2013108272A2/en
Publication of WO2013108272A3 publication Critical patent/WO2013108272A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a blood stage malaria vaccine. The vaccine comprises merozite antigens. The merozite antigens are selected from the group consisting of PfF2, PfRHl, PfRH2, PfRH4, PfRH5, AARP and PfMSP-fusion. The vaccine targets merozite surface proteins and the erythrocyte binding domains of multiple parasite adhesins blocking their interaction with their receptors and thus inhibiting erythrocyte invasion. The inventions also provide a method of treatment wherein the antigens block the sialic acid independent as well as sialic acid dependent binding of the parasite P. falciparum to the erythrocyte.
PCT/IN2013/000041 2012-01-20 2013-01-21 Blood stage malaria vaccine WO2013108272A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN177/DEL/2012 2012-01-20
IN177DE2012 2012-01-20

Publications (2)

Publication Number Publication Date
WO2013108272A2 WO2013108272A2 (en) 2013-07-25
WO2013108272A3 true WO2013108272A3 (en) 2013-12-12

Family

ID=47844417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000041 WO2013108272A2 (en) 2012-01-20 2013-01-21 Blood stage malaria vaccine

Country Status (1)

Country Link
WO (1) WO2013108272A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201309431D0 (en) * 2013-05-24 2013-07-10 Isis Innovation Treatment and prevention of malaria
US20170095547A1 (en) * 2014-06-02 2017-04-06 The Johns Hopkins University Malarial antigens derived from subtilisin-like protease 2 and vaccines and methods of use
GB201413530D0 (en) 2014-07-30 2014-09-10 Isis Innovation Treatment and prevention of malaria
MX2018004802A (en) 2015-10-19 2018-09-06 Cadila Healthcare Ltd New adjuvant and vaccine composition containing the same.
EP3416681A4 (en) * 2016-02-17 2020-03-18 Camris International, Inc. Novel antigen for use in malaria vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012292A2 (en) * 2000-08-07 2002-02-14 International Centre For Genetic Engineering And Biotechnology Method of polypeptide renaturation

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SG70625A1 (en) 1991-03-01 2000-02-22 Minnesota Mining & Mfg 1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
ATE188613T1 (en) 1992-06-25 2000-01-15 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
HU219056B (en) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
AU681687B2 (en) 1993-07-15 1997-09-04 Minnesota Mining And Manufacturing Company Imidazo(4,5-c)pyridin-4-amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DK1005368T3 (en) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
DE69838992T2 (en) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Oil-in-water emulsions with saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999040936A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6606617B1 (en) 1998-09-24 2003-08-12 International Business Machines Corporation Optimized technique for prefetching LOB table space pages
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
DE60012711T2 (en) 1999-03-26 2005-08-18 Vical, Inc., San Diego ADJUVANS COMPOSITIONS FOR INCREASING THE IMMUNE RESPONSE TO POLYNUCLEOTIDE-BASED VACCINES
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
JP2003509452A (en) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム Adjuvant containing polyoxyethylene alkyl ether or ester and at least one nonionic surfactant
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
ES2298269T3 (en) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. MODULATION OF THE IMMUNO-STIMULATING ACTIVITY OF OLIGONUCLEOTIDIC ANALOGS IMMUNO-STIMULANTS THROUGH POSITIONAL CHEMICAL CHANGES.
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
EP1372706B1 (en) 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
CN1599623B (en) 2001-09-14 2011-05-11 赛托斯生物技术公司 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
DE60234376D1 (en) 2001-11-27 2009-12-24 Anadys Pharmaceuticals Inc 3-BETA-D-RIBOFURANOSYLTHIAZOLO (4,5-DELTA) PYRIDIMINE NUCLEOSIDE AND ITS USE
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
CA2496246A1 (en) 2002-08-23 2004-03-04 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
EP1587473A4 (en) 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic Thiosemicarbazones as anti-virals and immunopotentiators
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
CA2520124A1 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
US20090175895A1 (en) 2007-11-05 2009-07-09 The Walter And Eliza Hall Institute Of Medical Research Methods and compositions for treating and preventing malaria
WO2010127398A1 (en) 2009-05-05 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Plasmodial polynucleotides, proteins and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012292A2 (en) * 2000-08-07 2002-02-14 International Centre For Genetic Engineering And Biotechnology Method of polypeptide renaturation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN LIN ET AL: "An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum.", PLOS PATHOGENS, vol. 7, no. 9, E1002199, September 2011 (2011-09-01), pages 1 - 19, XP002700074, ISSN: 1553-7374 *
DEEPAK GAUR ET AL: "Molecular interactions and signaling mechanisms during erythrocyte invasion by malaria parasites", CURRENT OPINION IN MICROBIOLOGY, vol. 14, no. 4, 29 July 2011 (2011-07-29), pages 422 - 428, XP028382130, ISSN: 1369-5274, [retrieved on 20110716], DOI: 10.1016/J.MIB.2011.07.018 *
JIANG LUBIN ET AL: "Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 108, no. 18, 3 May 2011 (2011-05-03), pages 7553 - 7558, XP002700072, ISSN: 1091-6490 *
LOPATICKI SASH ET AL: "Reticulocyte and erythrocyte binding-like proteins function cooperatively in invasion of human erythrocytes by malaria parasites.", INFECTION AND IMMUNITY, vol. 79, no. 3, March 2011 (2011-03-01), pages 1107 - 1117, XP002700073, ISSN: 1098-5522 *
PANDEY ALOK K ET AL: "Identification of a potent combination of key Plasmodium falciparum merozoite antigens that elicit strain-transcending parasite-neutralizing antibodies.", INFECTION AND IMMUNITY, vol. 81, no. 2, February 2013 (2013-02-01), pages 441 - 451, XP009170779, ISSN: 1098-5522 *

Also Published As

Publication number Publication date
WO2013108272A2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
WO2010028015A3 (en) 2-oxo-1,2-dihydro-quinoline modulators of immune function
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
WO2012162561A3 (en) Multivalent and monovalent multispecific complexes and their uses
NZ599508A (en) Anticoagulant antidotes
EA201291157A1 (en) MULTIVALENT VACCINES WITH SYNTHETIC NANOSATORS
MX2014011186A (en) Method of enhancing efficacy of blood transfusions.
MX341578B (en) Treatment of osteoarthritis and pain.
WO2011163478A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2013101972A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2013108272A3 (en) Blood stage malaria vaccine
WO2013034979A3 (en) Crystalline forms of cabazitaxel
UA113623C2 (en) TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR
WO2011006143A3 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
WO2013020074A3 (en) A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
WO2013101451A8 (en) Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
EA201290849A1 (en) OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR (TFPI)
FR2944106B1 (en) METHOD OF DETERMINING INOSITOL HEXAPHOSPHATE (IHP).
WO2012010978A3 (en) A method of treating alzheimer's disease
WO2012047267A3 (en) Polyvalent immunogen
EA201300946A1 (en) ASYMMETRIC UREA AND THEIR MEDICAL APPLICATION
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
TN2013000388A1 (en) Anticoagulant antidotes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13708532

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13708532

Country of ref document: EP

Kind code of ref document: A2